Background: Important progress in the prophylaxis of chemotherapy-induced acute and delayed emesis has been achieved but some fundamental needs still remain that requires new, efficacious antiemetic drugs.
introduction
Significant progress has been achieved in the last 20 years in the prevention of chemotherapy-induced nausea and vomiting and, based on these results, recommendations have been suggested by some international organizations [1, 2] . For the prevention of acute emesis induced by highly emetogenic chemotherapy such as cisplatin, mechloretamine and dacarbazine, a combination of a 5-HT3 antagonist plus dexamethasone gives complete protection from vomiting in about 70-80% of patients. The recommended doses are dexamethasone, 20 mg orally or intravenously, followed by a single intravenous vial of a 5-HT3 antagonist before chemotherapy. The 5-HT3 antagonist may also be administered orally (i.e., granisetron 2 mg or ondansetron 24 mg before chemotherapy).
Inferior results have been obtained in the prevention of cisplatin-induced delayed emesis, arbitrarily defined as emesis that starts or persists after 24 h from cisplatin administration; in fact, in this case the complete protection from vomiting achieved with the recommended regimens of dexamethasone plus metoclopramide or dexamethasone plus a 5-HT3 antagonist is only 50-60%. No dose-finding studies have been published evaluating the optimal dose of dexamethasone, metoclopramide or a 5-HT antagonist for the prevention of cisplatin-induced delayed emesis [1, 2] .
For the prevention of acute emesis induced by moderately emetogenic chemotherapy, such as cyclophosphamide, epirubicin, doxorubicin and carboplatin used alone or in combination, the combination of dexamethasone and a 5-HT3 antagonist induced about 80-90% complete protection from vomiting. The recommeded doses are dexamethasone, 8 mg orally or intravenously, followed by a single intravenous vial of a 5-HT3 antagonist before chemotherapy. Also in this case the 5-HT3 antagonist can be administered orally (i.e., granisetron 2 mg/day or ondansetron 8 mg two times a day).
For the prevention of delayed emesis in these patients oral dexamethasone is recommended. Alternatively, a 5-HT3 antagonist can be used. Complete protection from delayed vomiting in this case is about 70% in patients who did not have acute emesis and 20-30% in patients who did.
For the prevention of acute and delayed emesis induced by high-dose chemotherapy a combination of dexamethasone plus a 5-HT3 antagonist administered for several days is recommended but unfortunately, only 20-30% of patients achieve complete protection from vomiting.
Considering these results it is clear that we need new, more efficacious antiemetic drugs to counteract the emetic stimulus in our patients. Aprepitant and palonosetron are two recently approved new antiemetic drugs that will be now described. nervous system that can induce emesis when injected into the ferret [3] . Substance P exerts its biological effects by binding to the tachykinin neurokinin NK1 receptor. Aprepitant is a NK1 receptor antagonist, that differently from the 5-HT3 antagonists which appear to work primarily at a peripheral site, requires entry into the central nervous system to exert its antiemetic effect. In animal models, NK1 receptor antagonists are able to antagonize a large spectrum of emetic stimulus such as those induced by apomorphine, morphine, copper sulfate, ipecac, radiation, chemotherapy, motion and anesthesia [3] .
cisplatin-treated patients
Interesting results have been achieved with aprepitant in some phase II studies where this drug was combined with a 5-HT3 antagonist and dexamethasone for the prevention of cisplatin-induced acute and delayed emesis.
In a three-arm trial all 159 patients received granisetron 10 lg/kg intravenously and dexamethasone 20 mg orally before cisplatin [4] . In addition, patients received the NK1 receptor antagonist MK-869, 400 mg orally on day 1 (group 1) or MK-869, 400 mg orally on day 1 and 300 mg orally on day 2-5 (group 2) or placebo (group 3). Complete protection from acute vomiting was significantly superior on day 1 in patients receiving the NK1 antagonist (94% vs. 93% vs. 67%, respectively, in group 1, 2 and 3). Complete protection from delayed emesis (day 2-5) was significantly superior (78% vs. 82% vs. 33%, respectively). The superiority of the NK1 antagonist with respect to placebo in the prophylaxis of delayed emesis can mean either that the NK1 antagonist is really superior or that its superiority can be due to the better results obtained in the first 24 h that persist even in the subsequent days, and therefore, to a dependence effect. The distinction between these two results can be made only with a multifactorial analysis comparing the results obtained in the prevention of delayed emesis adjusted for the results obtained in the prevention of acute emesis. Unfortunately, this analysis was not carried out neither in this study nor in the other published subsequently [5] .
In another phase II study in 53 patients the NK1 antagonist, L-758, 298, 60 and 100 mg single dose intravenously before cisplatin, was compared to ondansetron, 32 mg single dose intravenously [6] . Complete protection from acute vomiting was achieved by 37% and 52% of patients, respectively; despite this, complete protection from delayed vomiting was superior in patients receiving the NK1 antagonist (72% versus 30%).
These results were confirmed in two other double-blind phase II studies. In the first, carried out in 177 patients, the standard antiemetic prophylaxis of ondansetron 32 mg iv and dexamethasone 20 mg iv was compared with L-758,298, 100 mg iv, plus dexamethasone, 20 mg iv or with with L-758, 298, 100 mg iv plus dexamethasone 20 mg iv on day 1 plus MK-869, 300 mg orally on day 2-5 [7] . Ondansetron plus dexamethasone was significantly superior to the NK1 antagonist administered on day 1 or on day 1 and day 2-5, always combined with dexamethasone, in the prevention of acute emesis (complete protection from vomiting in 84% vs.
47% and 49% of patients); however, patients receiving the NK1 antagonist achieved better control of delayed emesis (complete protection in 41% vs. 61% and 65%, respectively).
In the second study 351 patients were randomized to receive granisetron, 10 lg/kg iv and dexamethasone, 20 mg iv (arm 1) or this regimen combined with MK-869, 400 mg orally on day 1 and 300 mg on day 2-5 (arm 2), or MK-869, 400 mg orally on day 0 and day 1 and 300 mg on day 2-5, plus dexamethasone (arm 3) or MK-869, 400 mg orally on day 1 and 300 mg on day 2-5, plus dexamethasone (arm 4) [8] . The addition of the NK1 antagonist to granisetron plus dexamethasone significantly increased complete protection from acute vomiting with respect to granisetron plus dexamethasone alone (80% vs. 57%), while arm 3 and arm 4 were inferior with respect to arm 1 and 2 (complete protection in 46% and 43% of patients). Despite these results, complete protection from delayed vomiting was higher with arm 3 and 4 than with arm 1 (29%, 63%, 51% and 57% with arm 1, 2, 3, and 4, respectively).
In conclusion, the results of phase II studies suggest that NK1 antagonists combined with a 5-HT3 antagonist and dexamethasone seem to significantly increase complete protection from cisplatin-induced acute vomiting. Furthermore, the NK1 antagonist combined with dexamethasone is significantly less efficacious that the 5-HT3 antagonist plus dexamethasone combination in the prevention of cisplatin-induced acute emesis. Concerning cisplatin-induced delayed emesis, NK1 antagonists are probably more efficacious than placebo but their efficacy with respect to the standard combination of metoclopramide plus dexamethasone or a 5-HT3 antagonist plus dexamethasone remains to be evaluated.
For the identification of the optimal dose of aprepitant in cisplatin-treated patients, a randomized double-blind study evaluating oral pre-chemotherapy doses of aprepitant from 40 to 375 mg was carried out. This study concluded that a single 125 mg oral dose had ''the most favorable benefit:risk profile'' [9] . Thererfore, this 125 mg dose was used in the phase III studies of aprepitant, and it is the dose that has been approved by regulatory authorities.
Recently, two phase III studies have been published in which the standard treatment (ondansetron 32 mg iv plus oral dexamethasone 20 mg in the first 24 h and oral dexamethasone 8 mg twice daily on days 2-4) was compared to an aprepitant regimen (oral aprepitant 125 mg plus ondansetron 32 mg iv and oral dexamethasone 12 mg in the first 24 h; oral aprepitant 80 mg plus oral dexamethasone 8 mg on day 2 and 3 and oral dexamethasone 8 mg on day 4). In the aprepitant arm the dexamethasone dose was reduced due to a pharmacokinetic interaction with aprepitant that increases its plasma level more than two-fold. In the first study 569 patients were enrolled [10] . Complete response (no vomiting and no rescue treatment) was significantly superior with aprepitant compared to the standard treatment (63% versus 43% on days 1-5, 83% versus 68% on day 1 and 68% versus 47% on days 2-5, respectively). Complete protection from nausea was also significantly superior with aprepitant.
In the second study 530 patients were enrolled. Aprepitant induced a significantly superior complete response when Annals of Oncology symposium article compared to standard treatment (73% versus 52% on days 1-5, 89% versus 78% on day 1 and 75% versus 56% on days 2-5) [11] . Complete response from nausea was not significantly different. In both studies adverse effects were mild and not significantly different between the two groups of patients. In conclusion, in both studies aprepitant significantly increased antiemetic efficacy and its combination with a 5-HT3 antagonist and dexamethasone should be considered the new standard option for the prevention of cisplatin-induced acute emesis.
An analysis of an extension of the two studies, in which multiple cycles (maximum 6) were permitted, confirmed that the aprepitant combination is significantly superior during all six cycles of chemotherapy [12] .
Given the different antiemetic regimens employed for acute prophylaxis, one can question whether a significant component of the improved efficacy of the aprepitant-containing arms during the delayed phase was due to a carryover effect from the different control rates during day one. A subsequent analysis of the combined database from these two phase III trials strongly suggests that aprepitant provided protection against delayed vomiting regardless of response in the acute phase [13] . In patients with acute vomiting, the proportion of patients with delayed vomiting was 85% and 68% in the control and aprepitant arms, respectively. In patients with no acute vomiting, the proportion with delayed vomiting was 33% and 17% on the control and aprepitant arms, respectively.
Unfortunately, in both studies the treatment of choice for cisplatin-induced delayed emesis was not used. The MASCC has recommended that in patients receiving cisplatin treated with a combination of aprepitant, a 5-HT3-receptor antagonist and dexamethasone to prevent acute vomiting and nausea, the combination of dexamethasone and aprepitant is suggested to prevent delayed emesis, on the basis of its superiority to dexamethasone alone [14] .
Our opinion is that in order to define the role of aprepitant in the prophylaxis of cisplatin-induced delayed emesis, it is necessary to carry out further studies in which all patients receive the same standard combination of aprepitant plus a 5-HT3 antagonist plus dexamethasone for the prevention of cisplatin-induced acute emesis, and, starting from 24 h after cisplatin administration, patients should be randomized to receive dexamethasone plus metoclopramide (or ondansetron) or dexamethasone plus aprepitant.
patients treated with moderately emetogenic chemotherapy
Before the introduction of the NK1 receptor antagonists, the standard option for the prevention of acute emesis induced by moderately emetogenic chemotherapy was the combination of dexamethasone plus a 5-HT3 receptor antagonist.
Recently, a double-blind study comparing oral aprepitant (125 mg) plus dexamethasone (12 mg) plus ondansetron (8 mg before and 8 mg 8 h after chemotherapy) on day 1 and aprepitant 80 mg on day 2 and 3, with oral ondansetron (8 mg before and 8 mg 8 h after) plus dexamethasone (20 mg) on day 1 and ondansetron 8 mg twice on day 2 and 3 in 866 patients with breast cancer receiving cyclophosphamide±doxorubicin or epirubicin has ben published [15] . Overall complete response on day 1-5 was significantly superior with the aprepitant regimen than with the control regimen (51% versus 42%) Complete response on day 1 and on days 2-5 was also significantly superior with aprepitant (76% versus 69% and 55% versus 49%, respectively). Adverse events were not significantly different between the two regimens. The superiority of the aprepitant combination was maintained throughout the entire duration of chemotherapy treatment (four cycles) [16] . Therefore, to prevent acute vomiting and nausea in women receiving a combination of anthracycline plus cyclophosphamide, a three-drug regimen including single-doses of a 5-HT3 antagonist, dexamethasone, and aprepitant given before chemotherapy is recommended. Of course, in patients who receive moderately emetogenic chemotherapy, not including a combination of anthracycline plus cyclophosphamide, a 5-HT3 antagonist plus dexamethasone still remains the antiemetic treatment of choice.
After the publication of the Warr study [15] aprepitant was considered superior to a 5-HT3-receptor antagonist in the prevention of delayed emesis induced by moderately emetogenic chemotherapy in breast cancer patients receiving a combination of anthracycline plus cyclophosphamide treated with a combination of aprepitant, a 5-HT3-receptor antagonist and dexamethasone to prevent acute nausea and vomiting. Therefore, MASCC recommended that in these patients aprepitant or dexamethasone be used to prevent delayed emesis. On the other hand, randomized, double-blind studies comparing aprepitant with dexamethasone for the prevention of delayed emesis induced by moderately emetogenic chemotherapy are needed to identify the best antiemetic prophylaxis against delayed emesis. Of course, in patients who do not receive aprepitant as part of the prophylaxis for acute emesis dexamethasone, or alternatively, a 5-HT3 antagonist, remains the treatment of choice.
side effects and interactions
In all studies examined, aprepitant was well-tolerated. When combined with dexamethasone plus a 5-HT3 antagonist for the prevention of acute emesis no significant differences in the incidence of side effects were shown with respect to dexamethasone and a 5-HT3 antagonist alone.
Aprepitant can increase plasma concentrations of coadministered agents that are metabolized through CYP3A4. This suggests that oral corticosteroid doses should be reduced by 50% when co-administered with aprepitant and intravenous doses by 25%. Furthermore, the potential effect of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (i.e., alprazolam, trizolam) should be considered. Aprepitant should not be used concurrently with terfenadine, astemizole, cisapride and pimozide and caution is requested when aprepitant is administered with the following chemotherapeutic agents that are metabolized by CYP3A4: etoposide, vinorelbine, docetaxel and paclitaxel. In the phase III studies in cisplatin-treated patients the incidence of adverse events was similar with respect to patients that did not receive CYP3A4-metabolized chemotherapy in one study, while in another the incidence was higher.
Aprepitant can decrease plasma concentrations of coadministered agents that are metabolized through CYP2C9. This means that it is necessary to closely monitor prothrombin time in patients receiving warfarin to establish and maintain the dose after completion of a 3-day regimen of aprepitant with each chemotherapy course. A potential effect of decreased plasma concentrations of tolbutamide should be also considered. Finally, the efficacy of oral contraceptives may be reduced during administration of aprepitant and therefore, alternative or backup methods of contraception should be used.
Finally, agents that strongly inhibit CYP3A4 (i.e., ketoconazole, ritonavir, clarithromycin) may increase plasma concentration of aprepitant, while agents that strongly induce CYP3A4 (i.e., rifampicin, phenytoin, carbamazepine, phenobarbital) may decrease plasma concentrations of aprepitant.
palonosetron
Palonsetron is a potent and selective 5-HT3-receptor antagonist with a high affinity for the 5-HT3 receptors. Its mean plasma elimination half life of about 40 h is substantially longer than that of ondansetron (4-6 h), granisetron (5-8 h), tropisetron (7 h ) and dolasetron (7 h). It is metabolized primarily by CYP2D6 and to a lesser extent by CYP3A and CYP1A2. There is no difference in the drug's metabolism between poor and extensive metabolizers of CYP2D6 substrates.
Age, hepatic disfunction or mild to moderate renal impairment have no clinically significant effect on the pharmacokinetics of palonosetron although total systemic exposure increases by 28% in patients with severe renal impairment compared with healthy subjects.
patients treated with highly emetogenic chemotherapy
One study, published only as an abstract, evaluated two single doses of palonosetron (0.25 mg and 0.75 mg i.v. before chemotherapy) versus ondansetron (32 mg iv) in 667 patients receiving highly emetogenic chemotherapy [17] . Only 67% of these patients received dexamethasone on day 1 combined with the 5-HT3 antagonist.
The complete response (no vomiting and no rescue treatment) as well as the tolerability was not significantly different on day 1 (59%, 65% and 57%, respectively with 0.25 mg and 0.75 mg of palonosetron and 32 mg of ondansetron), day 2-5 (45%, 48% and 39%) and day 1-5 (41%, 42% and 33%, respectively) among the three arms of the study.
patients treated with moderately emetogenic chemotherapy
Two studies in patients treated with moderately emetogenic chemotherapy demonstrated efficacy with a single intravenous dose of palonosetron 0.25 mg that was equal or better to a single intravenous dose of dolasetron or ondansetron in both the acute and delayed phase [18, 19] .
In the first study carried out in 563 patients a complete response on day 1 was obtained by 81% of patients receiving 0.25 mg, 73% of those receiving 0.75 mg of palonosetron and by 69% of those receiving ondansetron [18] . On day 2-5 the complete response was 74%, 65% e 55% while on day 1-5 it was 69%, 59% e 50%, respectively. The difference between palonosetron 0.25 mg and ondansetron on day 1 and on day 2-5 was statistically significant.
In the second study, carried out in 569 patients, a complete response on day 1 was achieved respectively by 63% and 57% of patients receiving 0.25 and 0.75 mg of palonosetron and by 53% of those receiving dolasetron 100 mg ev [19] . On day 2-5 and on day 1-5 complete response was superior with both doses of palonosetron and statistically significant (54%, 57% and 39%, and 46%, 47% and 34%, respectively).
In these two studies less than 5% of patients received dexamethasone combined with a 5-HT3 antagonist and, therefore, superior efficacy in the setting of dexamethasone as recommended by the consensus guidelines was not demonstrated.
Furthermore, 30-60% of enrolled patients with mild nausea were pretreated, and while we know that the distribution of pretreated patients was similar among the three arms, we do not know if the distribution among the three arms of patients with mild nausea was also similar.
In both studies no patients received a prophylaxis for delayed emesis and this can also influence the results. As with studies of other agents, it is possible that superiority in the initial 24 h explains much of the superiority observed in the delayed phase. Somewhat surprisingly, a higher dose of palonsetron was less effective than a lower dose although it was still numerically superior to the 5-HT3-receptor antagonist.
In conclusion, the role of palonosetron with respect to the old 5-HT3 antagonists remains to be verified when both are combined with dexamethasone in the first 24 h and with the recommended therapies for delayed emesis in subsequent days.
side effects
Palonosetron is generally well tolerated. Side effects are similar to those of the other 5-HT3 antagonists and include headache in about 10 % of patients and constipation in about 5% of patients.
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